Title: RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS Document date: 2018_12_19
ID: r79h9yzz_906
Snippet: In dogs with stages I/II surgically treated (n=12), recurrence occurred at a median diseaseâ€free survival time (DFS) of 20±49days (n=6); in the remaining 6 dogs recurrence was not observed until death. Among dogs with stages III/IV (n=11), the median overall survival time (OST) in TG was significantly higher (282±73days) than the median OST of dogs in CG (59±18days) (p=0.020). In TG, a stable disease (n=5) and partial response (n=1) was obse.....
Document: In dogs with stages I/II surgically treated (n=12), recurrence occurred at a median diseaseâ€free survival time (DFS) of 20±49days (n=6); in the remaining 6 dogs recurrence was not observed until death. Among dogs with stages III/IV (n=11), the median overall survival time (OST) in TG was significantly higher (282±73days) than the median OST of dogs in CG (59±18days) (p=0.020). In TG, a stable disease (n=5) and partial response (n=1) was observed at 180 days of treatment. Toceranib phosphate was maintained until progressive disease (n=1) or severe adverse effects (n=4) occurred. Grade 1 and 2 (n=3) gastrointestinal signs occurred initially (3â€4 weeks), and Grade 4 (n=4) after months causing treatment withdrawal.
Search related documents:
Co phrase search for related documents- adverse effect and progressive disease: 1, 2
- adverse effect and severe adverse effect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- adverse effect and survival time: 1, 2, 3
- adverse effect and treatment withdrawal: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date